The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

The discovery of novel synthetic compounds with drug-like properties is an ongoing
challenge in medicinal chemistry. Natural products have inspired the synthesis of …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

In addition to commonly associated environmental factors, genomic factors may cause
cerebral palsy. We performed whole-exome sequencing of 250 parent–offspring trios, and …

There is considerable inter-individual variability in susceptibility to weight gain despite an
equally obesogenic environment in large parts of the world. Whereas many studies have …

Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its
dynamics and continuous changes under external pressure, it is one of the major causes of …

Abstract Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one
of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 …

RNA quality control relies on co-factors and adaptors to identify and prepare substrates for
degradation by ribonucleases such as the 3′ to 5′ ribonucleolytic RNA exosome. Here …

EML4–ALK fusion, observed in about 3%–7% of human lung adenocarcinoma, is one of the
most important oncogenic drivers in initiating lung tumorigenesis. However, it still remains …